The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, summarizes the promising developments in immuno-oncology in the field of melanoma. Beyond solely employing checkpoint inhibition, a combination of immunotherapeutic techniques can be utilized, and Prof. Gebhardt briefly remarks on the SWOG S1801 (NCT03698019), OpACIN-neo (NCT02977052), and PRADO cohort that employ neoadjuvant immunotherapeutics with emerging clinical applications. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
